Sera Prognostics (SERA) TD Cowen 46th Annual Health Care Conference summary
Event summary combining transcript, slides, and related documents.
TD Cowen 46th Annual Health Care Conference summary
2 Mar, 2026Unmet need and clinical opportunity
Preterm birth affects 1 in 10 pregnancies, representing a significant and common healthcare challenge with few effective screening options.
Premature births lead to substantial long-term health complications and societal costs, with lifetime healthcare expenses for preterm individuals estimated to be 50x to 300x higher than those born full term.
PRIME trial results and feedback
The PRIME trial, a 5,000-person randomized controlled study, showed a 20% reduction in NICU admissions and a 56% reduction in births before 32 weeks using a bundled intervention.
The intervention bundle (aspirin, progesterone, nurse calls) is low-cost, low-risk, and well-received by clinicians, with ongoing interest in adapting it to various care models.
Statistically significant reductions in neonatal morbidity and mortality have driven strong support from neonatologists and payers.
Health economics and payer engagement
Number needed to screen is 4.2 to save one NICU day, and 40 to prevent one NICU admission, which is nearly four times better than current standards.
Payers quickly recognize the economic value, especially given the high costs associated with NICU stays.
Latest events from Sera Prognostics
- PRIME study validated efficacy, commercial expansion advanced, and cash runway secured.SERA
Q4 202518 Mar 2026 - PreTRM enables early, validated prediction of preterm birth, reducing NICU admissions and costs.SERA
Corporate presentation18 Mar 2026 - PreTRM enables early, accurate preterm birth risk prediction, improving outcomes and reducing costs.SERA
Corporate presentation2 Mar 2026 - Innovative preterm birth screening test shows strong clinical and economic impact, with broad adoption targeted.SERA
H.C. Wainwright 26th Annual Global Investment Conference 20243 Feb 2026 - Net loss narrowed 21% as cash runway extends to 2027 and pivotal PreTRM studies advance.SERA
Q2 20242 Feb 2026 - Genomic and proteomic innovations are reshaping newborn care, with adoption set to accelerate.SERA
UBS Genomic Medicine Conference2 Feb 2026 - Q3 revenue fell and losses widened, but PRIME study and new initiatives aim to drive growth.SERA
Q3 202416 Jan 2026 - Pivotal trials validate a cost-saving preterm birth risk test, poised for broad adoption.SERA
Piper Sandler 36th Annual Healthcare Conference11 Jan 2026 - Proteomics-based test enables early intervention, reducing preterm birth complications and costs.SERA
43rd Annual J.P. Morgan Healthcare Conference 202510 Jan 2026